Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
ln Vitro |
In A549 cells, aminoguanidine (100–1000 μM, 24 h) can lessen DOX-induced cellular inflammation and DNA damage [1]. In AR42J cells, aminoguanidine (100 μM, 30 min) can activate ERK and aid in cell rebuilding [1].
|
---|---|
ln Vivo |
A 50 mg/kg intraperitoneal dose of aminoguanidine shields coils from the hepatotoxic effects of CCl4 [3]. Aminoguanidine (200 mg/kg, intraperitoneal, one dose) in coil to prevent hepatotoxicity caused by cyclophosphamide (CP) [3].
|
Cell Assay |
Apoptosis analysis [1]
Cell Types: A549 Tested Concentrations: 100-1000 μM Incubation Duration: 24 h Experimental Results: Shows a protective effect on DOX-induced DNA damage and reduces DOX-induced apoptosis. 2]. Cell proliferation assay[2] Cell Types: AR42J Tested Concentrations: 100 μM Incubation Duration: 24-96 hrs (hours) Experimental Results: Cell proliferation increased Dramatically after 48 hrs (hours) of incubation. |
Animal Protocol |
Animal/Disease Models: Male Swiss albino mouse [3]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection 30 minutes before CCl4 administration Experimental Results: Inhibited serum AST levels, protected hepatotoxin-oxidation intermediate and renal damage, and had a protective effect [ 4]. Induces lipid peroxidation. Animal/Disease Models: Adult male Wistar rats [4] Doses: 200 mg/kg Route of Administration: intraperitoneal (ip) injection 1 hour before CP injection, and sacrificed 16 hrs (hrs (hours)) after CP injection. Experimental Results: Attenuated CP-induced MDA elevation and prevented CP-induced protein oxidation. Restored GSH levels and attenuated CP-induced increase in MPO activity. |
References |
[1]. Sabuncuoglu S. Antiapoptotic effect of aminoguanidine on doxorubicin-induced apoptosis. Mol Cell Biochem. 2014 Sep;394(1-2):129-35.
[2]. Chowdhury P. Aminoguanidine (AG) Induces Induced both Pro- and Antioxidant Effect in AR42J Cells, a Rat Pancreatic Tumor Cell Line. Ann Clin Lab Sci. 2017 Sep;47(5):572-580. PMID: 29066484. [3]. Al-Shabanah OA, et al. Protective effect of aminoguanidine, a nitric oxide synthase inhibitor, against carbon tetrachloride induced hepatotoxicity in mice. Life Sci. 2000;66(3):265-70. [4]. Abraham P, et al. Protective effect of aminoguanidine against cyclophosphamide-induced oxidative stress and renal damage in rats. Redox Rep. 2011;16(1):8-14. |
Molecular Formula |
CH7CLN4
|
---|---|
Molecular Weight |
110.545
|
CAS # |
1937-19-5
|
Related CAS # |
Aminoguanidine hemisulfate;996-19-0
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
Cl[H].N([H])([H])/C(=N/N([H])[H])/N([H])[H]
|
Synonyms |
GER-11; YM-585; Pimagedine, MDL-201228
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~904.57 mM)
DMSO : ~100 mg/mL (~904.57 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (22.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (904.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 9.0457 mL | 45.2284 mL | 90.4568 mL | |
5 mM | 1.8091 mL | 9.0457 mL | 18.0914 mL | |
10 mM | 0.9046 mL | 4.5228 mL | 9.0457 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.